Development of Physiologically Based Pharmacokinetic Model for Orally Administered Fexuprazan in Humans

Fexuprazan is a new drug candidate in the potassium-competitive acid blocker (P-CAB) family. As proton pump inhibitors (PPIs), P-CABs inhibit gastric acid secretion and can be used to treat gastric acid-related disorders such as gastroesophageal reflux disease (GERD). Physiologically based pharmacok...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Yoo-Seong, Kim, Min-Soo, Lee, Nora, Lee, Areum, Chae, Yoon-Jee, Chung, Suk-Jae, Lee, Kyeong-Ryoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229463/
https://www.ncbi.nlm.nih.gov/pubmed/34072547
http://dx.doi.org/10.3390/pharmaceutics13060813

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229463/
https://www.ncbi.nlm.nih.gov/pubmed/34072547
http://dx.doi.org/10.3390/pharmaceutics13060813

Ejemplares similares